CX3CL1 expression in the conjunctiva is involved in immune cell trafficking during toxic ocular surface inflammation

Inappropriate expression of the chemokine CX3CL1 is reportedly known to act on inflammatory conditions in extraocular immune diseases. We studied the expression and effects of CX3CL1 in human patients, cultured human conjunctival cells, and transgenic mice exposed to benzalkonium chloride (BAC), a c...

Full description

Saved in:
Bibliographic Details
Published in:Mucosal immunology 2012-11, Vol.5 (6), p.702-711
Main Authors: Denoyer, A, Godefroy, D, Célérier, I, Frugier, J, Riancho, L, Baudouin, F, Rostène, W, Baudouin, C
Format: Article
Language:English
Subjects:
631/250/256
631/250/347
631/250/98/571
Adult
Aged
Allergology
Animals
Antibodies
Benzalkonium Compounds - adverse effects
Biomedical and Life Sciences
Biomedicine
Cell Line
Cell Movement - drug effects
Cell Survival - drug effects
Chemokine CX3CL1 - genetics
Chemokine CX3CL1 - immunology
Conjunctiva - drug effects
Conjunctiva - immunology
Conjunctiva - metabolism
Conjunctivitis - chemically induced
Conjunctivitis - genetics
Conjunctivitis - immunology
Conjunctivitis - pathology
CX3C Chemokine Receptor 1
Epithelial Cells - drug effects
Epithelial Cells - immunology
Epithelial Cells - metabolism
Female
Gastroenterology
Gene Expression - drug effects
Humans
Immunology
Life Sciences
Male
Mice
Mice, Knockout
Middle Aged
Preservatives, Pharmaceutical - adverse effects
Receptors, Chemokine - deficiency
Receptors, Chemokine - genetics
Receptors, Chemokine - immunology
Signal Transduction - drug effects
Tumor Necrosis Factor-alpha - genetics
Tumor Necrosis Factor-alpha - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inappropriate expression of the chemokine CX3CL1 is reportedly known to act on inflammatory conditions in extraocular immune diseases. We studied the expression and effects of CX3CL1 in human patients, cultured human conjunctival cells, and transgenic mice exposed to benzalkonium chloride (BAC), a commonly used preservative in ophthalmic medications despite its proinflammatory properties, to determine whether CX3CL1 is involved in conjunctival inflammation. We report that CX3CL1 expression is increased in the conjunctiva of patients receiving BAC-containing medication, and correlates with clinical inflammation. BAC enhances the production of CX3CL1 in a conjunctival epithelial cell line, through the tumor-necrosis factor-α pathway, which attracts specific leukocyte subsets. In vivo , BAC-induced macrophage infiltration and subsequent inflammation of the conjunctiva is decreased in CX3CR1-deficient mice as compared with CX3CR1 +/+ controls. This translational study opens new avenue to investigate ocular surface disorders by focusing on chemokine-related inflammation and immune cell trafficking in the ocular conjunctival mucosa.
ISSN:1933-0219
1935-3456
DOI:10.1038/mi.2012.43